Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$125B
1-Year Return
23.89%
This Quarter Return
+11.07%
1 Year Return
+23.89%
3 Year Return
+93.04%
5 Year Return
+163.06%
10 Year Return
+400.91%
AUM
$25.2B
AUM Growth
+$4.86B
(+24%)
Cap. Flow
+$2.92B
Cap. Flow
% of AUM
11.61%
Top 10 Holdings %
Top 10 Hldgs %
25.97%
Holding
1,178
New
57
Increased
860
Reduced
151
Closed
43
Top Buys
| 1 |
Apple
AAPL
|
$215M |
| 2 |
Microsoft
MSFT
|
$181M |
| 3 |
Amazon
AMZN
|
$112M |
| 4 |
Tesla
TSLA
|
$80.9M |
| 5 |
Meta Platforms (Facebook)
META
|
$66.7M |
Top Sells
| 1 |
iShares Global REIT ETF
REET
|
$20.2M |
| 2 |
JD.com
JD
|
$15.7M |
| 3 |
Ambarella
AMBA
|
$14.2M |
| 4 |
TopBuild
BLD
|
$12M |
| 5 |
NetEase
NTES
|
$10.9M |
Sector Composition
| 1 | Technology | 26.54% |
| 2 | Consumer Discretionary | 12.51% |
| 3 | Healthcare | 12.26% |
| 4 | Financials | 11.23% |
| 5 | Communication Services | 9.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Fate Therapeutics
FATE
$116M
| $315K | ﹤0.01% |
5,230
+1,119
| +27% | +$67.4K |
|
1002
Merus
MRUS
$5.1B
| $314K | ﹤0.01% |
10,163
-1,659
| -14% | -$51.3K |
|
1003
Ultragenyx Pharmaceutical
RARE
$3.07B
| $309K | ﹤0.01% |
3,667
+922
| +34% | +$77.7K |
|
|
UHT
1004
Universal Health Realty Income Trust
UHT
$574M
| $309K | ﹤0.01% |
5,156
+493
| +11% | +$29.5K |
|
1005
Precigen
PGEN
$1.3B
| $306K | ﹤0.01% |
76,904
+29,751
| +63% | +$118K |
|
1006
Amicus Therapeutics
FOLD
$2.46B
| $305K | ﹤0.01% |
25,186
-8,955
| -26% | -$108K |
|
1007
Immatics
IMTX
$761M
| $304K | ﹤0.01% |
23,634
-4,954
| -17% | -$63.7K |
|
1008
Arcturus Therapeutics
ARCT
$485M
| $301K | ﹤0.01% |
7,611
-2,790
| -27% | -$110K |
|
|
CYBE
1009
DELISTED
Cyberoptics Corp
CYBE
| $301K | ﹤0.01% |
6,375
-6,989
| -52% | -$330K |
|
1010
Maravai LifeSciences
MRVI
$363M
| $300K | ﹤0.01% |
7,552
+1,761
| +30% | +$70K |
|
1011
ProQR Therapeutics
PRQR
$258M
| $300K | ﹤0.01% |
37,113
-10,542
| -22% | -$85.2K |
|
1012
Paymentus
PAY
$4.62B
| $299K | ﹤0.01% |
+8,799
| New | +$299K |
|
1013
Fulcrum Therapeutics
FULC
$414M
| $298K | ﹤0.01% |
+16,742
| New | +$298K |
|
|
XXII
1014
22nd Century Group
XXII
$6.47M
| – | – |
0
| – | -$190K |
|
1015
ACI Worldwide
ACIW
$5.19B
| $293K | ﹤0.01% |
8,390
-472
| -5% | -$16.5K |
|
|
PAYA
1016
DELISTED
Paya Holdings Inc. Class A Common Stock
PAYA
| $289K | ﹤0.01% |
41,375
+9,140
| +28% | +$63.8K |
|
1017
Iovance Biotherapeutics
IOVA
$901M
| $288K | ﹤0.01% |
15,098
-3,753
| -20% | -$71.6K |
|
1018
Repay Holdings
RPAY
$506M
| $287K | ﹤0.01% |
14,700
+215
| +1% | +$4.2K |
|
1019
Arrowhead Research
ARWR
$4.02B
| $284K | ﹤0.01% |
4,065
-263
| -6% | -$18.4K |
|
1020
Blackbaud
BLKB
$3.23B
| $284K | ﹤0.01% |
3,573
-1,045
| -23% | -$83.1K |
|
1021
4D Molecular Therapeutics
FDMT
$340M
| $284K | ﹤0.01% |
+12,538
| New | +$284K |
|
|
ADAP
1022
Adaptimmune Therapeutics
ADAP
$10.9M
| $281K | ﹤0.01% |
69,140
+8,292
| +14% | +$33.7K |
|
|
BFS
1023
Saul Centers
BFS
$812M
| $279K | ﹤0.01% |
5,198
+628
| +14% | +$33.7K |
|
|
BLUE
1024
DELISTED
bluebird bio
BLUE
| $279K | ﹤0.01% |
1,318
+488
| +59% | +$103K |
|
|
CLLS
1025
Cellectis
CLLS
$269M
| $277K | ﹤0.01% |
31,607
+11,858
| +60% | +$104K |
|